Business Wire

Fluidstack to Deploy Energy Efficient Exascale GPU Clusters in Europe in Collaboration With Borealis Data Center, Dell Technologies and NVIDIA

Share

Fluidstack, the AI Cloud Platform, today announced it is deploying and managing Exascale clusters across Iceland and Europe in collaboration with Borealis Data Center, Dell Technologies and NVIDIA. The clusters will allow Fluidstack to further deliver a wider array of service options and meet the strong demand for its service offerings from customers around the world.

“Our mission has always been to support the most exceptional AI labs, researchers and enterprises on the planet,” said Cesar Maklary, co-founder and president of Fluidstack. “In collaboration with Borealis, Dell and NVIDIA, we can rapidly deploy high-density GPU supercomputers for both European and global customers, all while using 100% renewable energy.”

Sustainable Growth with Borealis

Borealis Data Center, a leader in green data center infrastructure, will provide Fluidstack with facilities powered by 100% renewable energy. Located in Iceland and operating across the Nordics, Borealis’ facilities benefit from a cold climate and renewable hydro and geothermal power.

“This partnership highlights a shared commitment to enabling next-generation AI while minimizing its environmental impact,” said Björn Brynjúlfsson, CEO of Borealis.

Working with Dell Technologies for Advanced AI Workloads

Fluidstack will leverage Dell PowerEdge XE9680 servers, optimized for AI workloads with NVIDIA HGX H200. Combined with NVIDIA’s Quantum-2 InfiniBand networking Dell servers offer best-in-class performance and reliability for AI workloads.

“We’re looking forward to working with Fluidstack, Borealis and NVIDIA to deploy advanced, sustainable AI infrastructure across Europe,” said Arun Narayanan, senior vice president, Compute and Networking, Dell Technologies. “Dell PowerEdge XE9680 servers combined with NVIDIA’s GPUs and networking are purpose-built to efficiently support rapidly growing AI workloads, helping customers achieve unprecedented efficiency and scalability while lowering cost and energy usage.”

Building the Backbone for Europe’s AI Innovation

With Europe’s AI data center market projected to reach $29.8 billion by 2026, Fluidstack is positioned at the forefront of enabling breakthrough AI research and innovation across the continent.

Fluidstack’s customers, including Poolside and Character AI, rely on its rapid deployment and exceptional support to power their AI workloads. Jason Warner, CEO of Poolside, said:
Fluidstack has been instrumental in helping us scale our AI capabilities. Their speed, reliability, and customer support are second to none.

About Fluidstack

Fluidstack is the AI Cloud Platform. Built for the leaders in AI, we enable rapid access to high-performance exa-scale compute. We are infrastructure agnostic, allowing our customers to scale compute across 100+ Infrastructure Partners globally through a single unified platform. Trusted by companies like Poolside and Character, Fluidstack delivers best-in-class performance for training and inference workloads running on multi-thousand GPU clusters. To learn more, visit www.fluidstack.io.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250325464584/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release

POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base

Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release

Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,

Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release

Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of

Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release

New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou

Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release

The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye